Background: Portal vein thrombosis (PVT) is reported in 10–40% of hepatocellular carcinoma (HCC) patients. The development of PVT is a multifactorial process, resulting from a reduction in portal blood flow and hypercoagulability. Methods: We evaluated 44 HCC patients with PVT, 50 HCC patients without PVT and 50 healthy subjects. Homocysteine (Hcy), Vitamin B6, Vitamin B12 and folate were measured. Results: Hcy in HCC patients with PVT is significant higher than the patients without PVT and controls subjects. Conclusion: Total Hcy is a sensitive marker of PVT in patients with HCC.
Blood homocysteine levels are increased in hepatocellular carcinoma patients with portal vein thrombosis. A single centre retrospective cohort study / Malaguarnera, M.; Catania, V. E.; Borzi, A. M.; Malaguarnera, S.; Madeddu, R.; Bertino, G.; Latteri, S.. - In: INTERNATIONAL JOURNAL OF SURGERY OPEN. - ISSN 2405-8572. - 15:(2018), pp. 60-65. [10.1016/j.ijso.2018.11.001]
Blood homocysteine levels are increased in hepatocellular carcinoma patients with portal vein thrombosis. A single centre retrospective cohort study
Madeddu R.Membro del Collaboration Group
;
2018-01-01
Abstract
Background: Portal vein thrombosis (PVT) is reported in 10–40% of hepatocellular carcinoma (HCC) patients. The development of PVT is a multifactorial process, resulting from a reduction in portal blood flow and hypercoagulability. Methods: We evaluated 44 HCC patients with PVT, 50 HCC patients without PVT and 50 healthy subjects. Homocysteine (Hcy), Vitamin B6, Vitamin B12 and folate were measured. Results: Hcy in HCC patients with PVT is significant higher than the patients without PVT and controls subjects. Conclusion: Total Hcy is a sensitive marker of PVT in patients with HCC.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
